Month: January 2025

The collaboration will integrate Google’s ML core with Synaptics Astra™ AI-Native hardware and open-source software to accelerate the development of context-aware devices. SAN JOSE, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) today announced that it is collaborating with Google on Edge AI for the IoT to define the optimal implementation of multimodal processing for context-aware computing. The collaboration will integrate Google’s MLIR-compliant ML core on the Synaptics Astra™ hardware with open-source software and tools. The combination will accelerate the development of AI devices for the IoT that support the processing of vision, image, voice, sound, and other modalities that provide context for seamless interactivity in applications such as wearables, appliances, entertainment,...

VANCOUVER, British Columbia, Jan. 02, 2025 (GLOBE NEWSWIRE) — West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF) is pleased to announce that on December 31, 2024 it entered into a completed credit agreement (the “Loan Agreement”) with Nebari Natural Resources Credit Fund II LP (“Nebari”) pursuant to which the Company will borrow up to a maximum principal amount of US$35 million (the “Credit Facility”) to be issued in three tranches of : (i) US$15 million (“Tranche 1”), (ii) US $15 million (“Tranche 2”), and (iii) US$5 million (“Tranche 3” and together with Tranche 1 and Tranche 2, the “Tranches” and each a “Tranche”). Tranche 1 was drawn down on December 31, 2024. The Credit Facility was first announced on October 17, 2024, when the Company and Nebari had entered into a non-binding...

Heineken® 0.0 commissions new anthropological study, revealing going alcohol-free can still raise eyebrows – especially among Gen Zers“Heineken 0.0? Are you on diet?” People often assume there’s a reason for drinking non-alcoholic beer. We are challenging this assumption the Heineken way. Proving that no reasons are needed to enjoy Heineken 0.0. Great taste and Zero Alcohol pack a perfect combination for any occasion. Now you can.“Heineken 0.0? Are you driving?” People often assume there’s a reason for drinking non-alcoholic beer. We are challenging this assumption the Heineken way. Proving that no reasons are needed to enjoy Heineken 0.0. Great taste and Zero Alcohol pack a perfect combination for any occasion. Now you can.Heineken 0.0? Are you working late?” People often assume...

« Sword is embarking on the implementation of its 2028 Business Plan with great confidence, backed by the excellence of its employees, the loyalty of its customers and the solidity of its investors.We are approaching this new period with a clear strategic vision, anticipating market developments to transform every challenge, risk or constraint into a real opportunity for growth. » Jacques MottardChairman & CEO OUR STRATEGIC PRINCIPLES A High-Performance, Committed Management Organisation At Sword, we embody a management style based on action and involvement. Every manager, at every level, plays a dual role of, “doing ” and “getting things done “, to boost efficiency and cohesion. Long-term and Multidimensional Growth Our balanced and ambitious growth strategy is built around three key areas for the next four...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca. The...

License continues the proliferation of Weebit’s innovative non-volatile memory technology HOD HASHARON, Israel, Jan. 01, 2025 (GLOBE NEWSWIRE) — Weebit Nano Limited (ASX:WBT) (Weebit or Company), a leading developer and licensor of advanced memory technologies for the global semiconductor industry, has licensed its resistive random access memory (ReRAM) technology to tier-1 semiconductor supplier, onsemi (Nasdaq:ON). Under the terms of the agreement, Weebit ReRAM IP will be integrated into onsemi’s Treo platform, to provide embedded non-volatile memory (NVM). Weebit ReRAM integration into a Bipolar CMOS, DMOS (BCD) process provides a low-power, cost-effective NVM that has proven excellent retention at high temperatures. Coby Hanoch, CEO of Weebit Nano, said: “We are delighted to announce Weebit’s latest commercial agreement with...

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (“SHPL”) for approximately US$608 million (RMB4,478 million) in cash, to GP Health Service Capital Co., Ltd...